The global IVD quality control market is projected to reach USD 1.4 billion by 2026 from USD 1.1 billion in 2021, at a CAGR of 5.3% during the forecast period.
The "Global In Vitro Diagnostics (IVD) Quality Control Market, by Source (Plasma, Whole Blood, Urine), Technology (Immunoassay, Hematology, Microbiology, Molecular Diagnostics), Manufacturer (Third-party, OEM), End Users (Hospitals, Lab) - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
The global IVD quality control market is projected to reach USD 1.4 billion by 2026 from USD 1.1 billion in 2021, at a CAGR of 5.3% during the forecast period. IVD testing plays a significant role in clinical decision-making.
The product & service segment holds the highest share of the total IVD quality control market during the forecast period
Based on product & service, the IVD quality control market is segmented into quality control products, data management solutions, and quality assurance services. The quality control products segment accounted for the largest share of the IVD quality control market in 2020.
The increasing number of accredited laboratories and mandates for the use of quality controls from regulatory bodies to ensure the accuracy of diagnostic test results are driving the growth of the IVD quality control products market.
Serum based controls drive the growth of the quality control products segment during the forecast period
Based on type, the IVD quality control products market is segmented into serum/plasma-based controls, whole blood-based controls, urine-based controls, and others. Serum/plasma-based controls are highly preferred by laboratories; this segment accounted for the largest share of the quality control products market in 2020.
The greater uptake of serum/plasma-based quality controls among laboratories and the wide application areas of these controls for various IVD tests are driving the market growth.
Molecular diagnostics segment accounted for the highest CAGR of the global IVD quality control market
Based on technology, the IVD quality control market is broadly segmented into clinical chemistry, immunochemistry, hematology, coagulation & hemostasis, microbiology, molecular diagnostics, and other technologies. The molecular diagnostics segment has the highest CAGR for the forecast period.
With the increased non-communicable disease burden, molecular diagnostic tests have been used in the field of oncology widely. Technological advancement in the field of molecular diagnostics is another driver for the growth of this industry.
Third-party controls accounted for the highest share for the IVD quality control market
Based on manufacturer, the IVD quality control market is segmented into third-party controls and OEM controls. The third-party controls segment accounted for the largest share of the global IVD quality control market in 2020.
The large share of this segment can be attributed to the increasing use of third-party quality controls across the globe to verify the accuracy and reliability of tests.
Based on end users, hospitals accounted for the highest share of the global IVD quality control market during the forecast period
The key end users of IVD quality controls studied in this report include hospitals, clinical laboratories, research & academic institutes, and other end users. The hospitals segment accounted for the largest share of the IVD quality control market in 2020, owing to the large volume of diagnostic tests carried out in hospitals.
North America is expected to account for the highest share for players operating in the global IVD quality control market
Geographically, the global IVD quality control market studied in this report is divided into five major regions-North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global IVD quality control market, followed by Europe.
The APAC region has the highest CAGR of the global IVD quality control market. The Asia Pacific is considered the most lucrative market for IVD quality controls, owing to the region's large patient population and rising healthcare needs.
- Increasing number of accredited clinical laboratories
- Growing adoption of third-party quality controls
- Rising demand for external quality assessment support
- Rising geriatric population and subsequent growth in the prevalence of chronic and infectious diseases
- Increasing adoption of Poc instruments in developed regions
- Additional costs and budget constraints in hospitals and laboratories
- Unfavorable reimbursement scenario for IVD tests
- Rising demand for multi-analyte controls
- Stringent product approval process
- Lack of regulations for clinical laboratory accreditation in several emerging countries
- Abbott Laboratories
- Alpha-Tec Systems, Inc.
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- Danaher Corporation
- Fortress Diagnostics
- Grifols, S.A.
- Helena Laboratories Corporation
- LGC Limited
- Maine Molecular Quality Controls, Inc. (MMQCI)
- Microbiologics, Inc.
- Microbix Biosystems Inc.
- Ortho Clinical Diagnostics
- Quidel Corporation
- Randox Laboratories Ltd.
- Roche Diagnostics
- Seegene Inc.
- Sero AS
- Siemens Healthineers
- Streck, Inc.
- Sun Diagnostics, Llc
- Sysmex Corporation
- Thermo Fisher Scientific, Inc.
- Zeptometrix Corporation
For more information about this report visit https://www.researchandmarkets.com/r/lizicb